Ilaris
Ilaris
Ilaris (pronounced /ɪˈlærɪs/), also known as canakinumab, is a monoclonal antibody designed for the treatment of various autoinflammatory syndromes. It is produced by Novartis, a Swiss multinational pharmaceutical company.
Etymology
The name "Ilaris" is a brand name given by Novartis. The generic name "canakinumab" follows the INN guidelines for monoclonal antibodies, with the suffix "-mab" indicating it is a monoclonal antibody, and "kin" referring to its target, interleukin-1 beta.
Usage
Ilaris is used to treat a number of conditions, including CAPS, SJIA, AOSD, and Gouty arthritis. It works by blocking the action of interleukin-1 beta, a part of the immune system that can cause inflammation and other symptoms in these conditions.
Related Terms
External links
- Medical encyclopedia article on Ilaris
- Wikipedia's article - Ilaris
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski